Original Research

Battlefield Acupuncture vs Ketorolac for Treating Pain in the Emergency Department

Author and Disclosure Information

 

References

Results

Sixty-one patients received BFA during the study period: 31 were excluded (26 received adjunct treatment in the ED, 2 had active cancer documented, 2 had an indication other than pain, and 1 received BFA outside of the ED), leaving 30 patients in the BFA cohort. During the study period, 1299 patients received ketorolac. These patients were selected using a random number generator and then screened to determine inclusion or exclusion in the study. We continued to randomly select patients for the ketorolac group until we had a similar number in each treatment group. Of these 148 patients who were randomly selected to be reviewed, 116 were excluded: 48 received adjunct treatment in the ED, 24 had no postintervention NRS pain score documented within 6 hours, 18 received ketorolac doses other than 15 mg, 12 received ketorolac outside the ED, 9 had no baseline NRS pain score documented, 3 presented with a NRS pain score of ≤ 3, and 2 had active cancer documented. The ketorolac cohort comprised 31 patients.

Baseline characteristics were similar between the 2 groups except for the average baseline NRS pain score, which was statistically significantly higher in the BFA vs ketorolac group (8.7 vs 7.7, respectively; P = .02). The mean age was 51 years in the BFA group and 48 years in the ketorolac group. Most patients in each cohort were male: 80% in the BFA group and 71% in the ketorolac group. The most common types of pain documented as the chief ED presentation included back, lower extremity, and head.

Table 1
Ten patients in the BFA group and 3 in the ketorolac group presented with lower extremity pain (P = .02) (Table 1).

Endpoints

The mean difference in NRS pain score was 3.9 for the BFA group and 5.1 for the ketorolac group. Both were clinically and statistically significant reductions (P = .03 and P < .01), but the difference between the intervention groups in NRS score reduction was not statistically significant (P = .07).

For the secondary endpoint of outpatient prescriptions written at discharge, there was no significant difference between the groups except for oral NSAIDs, which were more likely to be prescribed to patients who received ketorolac (P = .01).

Table 2
Patients who received BFA were more likely to receive oral muscle relaxants or topical analgesics, but the difference between the groups was not statistically significant (Table 2). There was no difference in the number of patients who received no prescriptions at ED discharge. Patients who received ketorolac were more likely to be admitted to the hospital (P = .049) (Table 3).
table 3
No AEs were observed in either treatment group during the study.

Subgroup Analysis

An analysis was performed for subgroups classified by baseline NRS pain score (mild: 4; moderate, 5 - 6; severe, 7 - 9; and very severe, 10). Data for mild pain was limited because a small number of patients received interventions. For moderate pain, the mean difference in NRS pain score for BFA and ketorolac was 3.5 and 3.8, respectively; for severe pain, 3.4 and 5.3; and for very severe pain, 4.6 and 6.4. There was a larger difference in the preintervention and postintervention NRS pain scores within severe pain and very severe pain groups.

figure
The mean difference in NRS pain score reduction between the intervention groups was not statistically significant for any subgroup (Figure).
table 4
A subgroup analysis also was performed comparing pain locations, although no statistically significant difference was found among the subgroups (Table 4).

Discussion

Both interventions resulted in a significant reduction in the mean NRS pain score of about 4 to 5 points within their group, and BFA resulted in a similar NRS pain score reduction compared with ketorolac 15 mg. Because the baseline NRS pain scores were significantly different between the BFA and ketorolac groups, a subgroup analysis revealed that BFA reduced mean NRS pain score in patients with severe and very severe pain but appears to be less beneficial for moderate pain, unlike the ketorolac results that showed a large reduction in all pain groups except for the small sample of patients with mild pain.

Pages

Recommended Reading

COVID can mimic prostate cancer symptoms
Federal Practitioner
Watch for buprenorphine ‘spiking’ in urine drug tests
Federal Practitioner
Link between knee pain, sleep disturbance related to daily activities
Federal Practitioner
Hydroxyurea underused in youth with sickle cell anemia
Federal Practitioner
Safety, efficacy of analgesics for low back pain ‘uncertain’
Federal Practitioner
Antidepressants benefit some patients with osteoarthritis pain
Federal Practitioner
Metabolic syndrome linked to knee pain in middle adulthood
Federal Practitioner
Cluster, migraine headache strongly linked to circadian rhythm
Federal Practitioner
New guidelines for cannabis in chronic pain management released
Federal Practitioner
IUD-released levonorgestrel eases heavy menstrual periods
Federal Practitioner